August 2016: Information about which proton pump inhibitors and H2-receptor antagonists are licensed for use and which are classed as off-label has been added to recommendation 1.7.1.
April 2015: Recommendation 1.2.5 has been amended to add the use of cryoprecipitate as further treatment.
Minor changes since publication
September 2023: In the section on resuscitation and initial management, we added links to the MHRA safety advice on direct-acting oral anticoagulants (DOACs) and NICE's technology appraisal guidance on andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban.
We also updated the off-label text on proton pump inhibitors and H2-receptor antagonists for recommendation 1.7.1, including that ranitidine is currently unavailable.